Degarelix Peptide: Firmagon, GnRH Antagonist Uses and Safety Limits
Degarelix (Firmagon) peptide guide covering GnRH antagonist biology, the advanced prostate cancer label, flare-free testosterone suppression and key safety limits.
Degarelix is a peptide drug with a very different evidence profile from research-market hormone peptides. It is a synthetic gonadotropin-releasing hormone (GnRH) receptor antagonist, sold under the brand name Firmagon, and it is used as a prescription injection for advanced prostate cancer.
The defining feature is mechanism. Unlike GnRH agonists such as leuprolide, degarelix blocks pituitary GnRH receptors directly and competitively. That means it lowers testosterone within days and avoids the initial hormone "flare" that agonists produce. This is a clinically important distinction, not a marketing slogan, and it shapes how degarelix is used and monitored.
For related endocrine context, compare this guide with gonadorelin, leuprolide, kisspeptin, what peptides are, and the peptide half-life guide. Because degarelix is injected, general handling concepts in how to inject peptides safely are useful background but never replace the label or a clinician's instructions.
This guide is educational and not medical advice. Degarelix is a prescription medicine for a serious oncologic indication. It should be started, monitored, changed or stopped only through qualified medical care.
Degarelix At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic decapeptide GnRH receptor antagonist. |
| Brand | Firmagon (degarelix for injection), developed by Ferring Pharmaceuticals. |
| Approved use | Treatment of patients with advanced prostate cancer (FDA, initial U.S. approval 2008). |
| Main effect | Rapid, profound testosterone suppression without an initial flare. |
| Route | Subcutaneous injection in the abdominal region only, by a healthcare professional. |
| Evidence type | FDA label, phase 3 trial CS21 and supporting pharmacology and extension studies. |
| Main safety frame | QT prolongation, hypersensitivity, injection-site reactions and the consequences of low testosterone. |
How A GnRH Antagonist Lowers Testosterone
Native GnRH is released in pulses from the hypothalamus and signals the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then drives testicular testosterone production. In prostate cancer, testosterone can fuel tumor growth, so lowering it to "castrate" levels (commonly defined as serum testosterone below 50 ng/dL) is the goal of androgen deprivation therapy.
Degarelix binds reversibly and competitively to pituitary GnRH receptors. By occupying those receptors, it immediately reduces LH and FSH release and therefore testosterone production. According to the FDA prescribing information, this produces a fast and profound suppression of testosterone.
The contrast with GnRH agonists is the heart of the degarelix story. An agonist first overstimulates GnRH receptors, briefly raising testosterone before the pituitary downregulates. That early rise is the testosterone surge, or clinical flare, that can transiently worsen disease and that often requires anti-androgen "flare protection." Degarelix has no agonist phase, so it does not cause that surge. In the pivotal trial, degarelix produced roughly a 94% drop in testosterone within three days, whereas the agonist comparator caused an initial increase.
Approval, Dosing And Administration
The FDA approved degarelix in 2008. The labeled indication is the treatment of patients with advanced prostate cancer. Firmagon is administered only by a healthcare professional, as a subcutaneous injection in the abdominal region.
The label describes a depot-style regimen. The starting dose is 240 mg, given as two 120 mg subcutaneous injections at a concentration of 40 mg/mL. The maintenance dose is 80 mg, given as a single subcutaneous injection at 20 mg/mL, administered every 28 days. These figures are reference values taken directly from the prescribing information; they describe how an approved oncology product is dosed and are not a recommendation, a self-administration protocol, or a suggestion that degarelix has any role outside prostate cancer care.
| Dose context | What the label supports | Important limit |
|---|---|---|
| Starting dose 240 mg | Two 120 mg subcutaneous injections to load the depot. | Given by a healthcare professional in the abdomen only. |
| Maintenance dose 80 mg | A single subcutaneous injection every 28 days. | Timing and monitoring follow the oncology label, not generic peptide schedules. |
| Castrate target | Suppression of testosterone below 50 ng/dL. | Achieved in over 96% of patients between day 28 and day 364 in the pivotal trial. |
The product forms a gel depot at the injection site, which is why a single subcutaneous dose can release drug slowly over weeks.
Pharmacokinetics And Half-Life
Degarelix has a long apparent half-life because of that depot, not because the molecule itself lingers in plasma. After a 240 mg subcutaneous starting dose, degarelix is eliminated in a biphasic fashion with a median terminal half-life of about 43 days. For the 80 mg maintenance dose, the mean terminal half-life is shorter, on the order of 28 to 29 days. The slow release from the subcutaneous depot is the main reason for these long values. For broader background on why formulation drives duration, see the peptide half-life guide.
Clinical Evidence And Its Limits
The central evidence is the phase 3 trial commonly referred to as CS21, published by Klotz and colleagues in BJU International in 2008. It was a 12-month, randomized, open-label, parallel-group study in 610 patients with prostate cancer, comparing degarelix (240 mg starting dose then 80 mg or 160 mg monthly) against monthly leuprolide 7.5 mg.
The primary endpoint, suppression of testosterone below 50 ng/dL from day 28 through day 364, was achieved in more than 96% of patients across groups, meeting the non-inferiority standard against leuprolide. The headline secondary finding was the early difference: degarelix lowered testosterone rapidly with no surge, while leuprolide produced an initial rise. Follow-up and extension analyses, including a one-arm crossover from leuprolide to degarelix, examined hormonal effects and PSA-defined recurrence in more detail.
Honesty about the limits matters. CS21 was an open-label study, and much of the degarelix literature centers on surrogate endpoints such as testosterone and PSA rather than long-term survival. Some pooled and retrospective analyses have suggested cardiovascular signals favoring GnRH antagonists in men with prior cardiovascular disease, but the strength of that evidence and how it should change practice remain actively debated. Degarelix's established, label-backed value is rapid flare-free castration in advanced prostate cancer, not any broader hormonal or wellness use.
Safety Limits
Degarelix safety follows from its mechanism and from the FDA label. Most adverse effects relate either to the injection itself or to the intended low-testosterone state.
| Safety issue | Why it matters |
|---|---|
| Injection-site reactions | Pain, erythema, swelling and induration are among the most common effects, especially with the starting dose. |
| QT/QTc prolongation | Androgen deprivation therapy with degarelix may prolong the QT interval; periodic ECG and electrolyte monitoring should be considered. |
| Hypersensitivity and anaphylaxis | Severe hypersensitivity to degarelix or any component is a contraindication; anaphylaxis, urticaria and angioedema have been reported post-marketing. |
| Liver enzyme elevations | Transaminase and GGT increases can occur; periodic liver monitoring may be appropriate. |
| Hot flashes and metabolic effects | Low testosterone causes hot flashes, weight increase, fatigue and can affect glucose, lipids and bone over time. |
| Embryo-fetal risk | Degarelix can cause fetal harm; although used in men, the label notes it is not indicated in women and can harm a fetus. |
Degarelix can also cause chills, increased blood pressure, decreased libido, gynecomastia and other effects tied to androgen deprivation. The common adverse reactions reported in trials include injection-site reactions, hot flashes, increased weight, fatigue and increases in transaminases and GGT.
Degarelix Versus Agonists And Other GnRH Peptides
The cleanest comparison is with leuprolide, the prototypical GnRH agonist. Both ultimately suppress testosterone, but the path differs. Leuprolide stimulates first and suppresses later, which is why agonist therapy can need flare protection at initiation. Degarelix antagonizes the receptor from the start, so castrate testosterone arrives within days and there is no surge.
Gonadorelin is essentially native GnRH and is used in diagnostic or pulsatile fertility-axis contexts, a goal that is the opposite of sustained suppression. Kisspeptin acts further upstream in the reproductive axis and has a distinct, largely investigational evidence story. The practical lesson is that "GnRH peptides" are not one interchangeable class: agonists, antagonists and upstream modulators have different kinetics, different first-dose behavior and different clinical roles.
How To Evaluate A Degarelix Claim
Ask a few focused questions before trusting any source.
First, is the claim about the approved use? Degarelix is labeled for advanced prostate cancer and is given by a clinician. Any suggestion of casual, self-directed or "hormone optimization" use is a red flag.
Second, does the source respect the antagonist mechanism? The defining feature is flare-free, rapid suppression. A source that conflates degarelix with agonist flare biology is unreliable.
Third, are dose figures presented as label reference values, not protocols? The 240 mg load and 80 mg monthly maintenance describe a supervised oncology regimen, not a do-it-yourself schedule.
Fourth, does the source mention the real safety profile, including QT prolongation, hypersensitivity, injection-site reactions and liver enzyme changes? Omitting these understates the risk.
Fifth, is it citing primary evidence such as the FDA label or the CS21 trial, rather than vendors or anecdote?
Bottom Line
Degarelix (Firmagon) is a genuine, FDA-approved peptide medicine: a GnRH receptor antagonist that delivers rapid, flare-free testosterone suppression in advanced prostate cancer. Its mechanism is its main advantage over GnRH agonists, and the pivotal CS21 trial supports both effective castration and the absence of an initial testosterone surge.
The same profile defines its limits. Degarelix is an oncology injection given by clinicians, with meaningful safety considerations including QT prolongation, hypersensitivity, injection-site reactions and the metabolic consequences of low testosterone. It is not a general hormone peptide, not a wellness product and not something to interpret without the label and specialist oversight.
References
DailyMed. FIRMAGON (degarelix) prescribing information.
U.S. Food and Drug Administration. FIRMAGON (degarelix for injection) Highlights of Prescribing Information.
Drugs@FDA. Degarelix (FIRMAGON) NDA 022201 approval history.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008.
Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of GnRH agonist and antagonist effect on prostate cancer. J Urol. 2011.
Schröder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase and biochemical recurrence in a phase 3 trial (CS21) comparing degarelix versus leuprolide in prostate cancer patients. Urology. 2010.
Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013.
Electronic Medicines Compendium. Firmagon 80 mg powder and solvent for solution for injection (Summary of Product Characteristics).
ClinicalTrials.gov. Efficacy and Safety Study of Degarelix in Patients With Prostate Cancer (CS21).